Clinical Study

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1A (Rebif®) In Patients With Relapsing Multiple Sclerosis

Posted Date: Sep 30, 2016

  • Investigator: Joseph Nicolas
  • Co-Investigator: Alecia Corcoran
  • Specialties: Multiple Sclerosis, Neurology
  • Type of Study: Drug

This study is being conducted by F. Hoffmann-La Roche Ltd. (Roche) and Genentech Inc, called “Sponsor” later on in this document. We want to confirm whether patients treated with ocrelizumab may experience even fewer clinical relapses (also called clinic

Criteria:

• You Must Be 18 To 55 Years Of Age. • You Must Pass The Screening Medical Examinations And Tests (Including A Pregnancy Test For Females Who Are Able To Become Pregnant During The Study); If You Or Your Female Partner (If You Are Male) Are Able To Becom

Keywords:

Relapsing-Remitting, Opera, Ocrelizumab, Multiple Sclerosis, Null

For More Information:

Alecia Boehl
513-558-0039
alecia.boehl@uc.edu

  • Search Clinical Studies

  • Research in the News

    CF Patients and Docs Use Shared Decision-Making Tool to Determine Regimens

    Physician-researchers at the University of Cincinnati have developed acomputerized decision-making model to promote shared decision-making withcystic fibrosis patients.